User Bulletin #2

ABI PRISM 7700 Sequence Detection System

December 11, 1997 (updated 10/2001)

Relative Quantitation of Gene Expression SUBJECT:

Introduction Amplification of an endogenous control may be performed to standardize the amount of sample RNA or DNA added to a reaction. For the quantitation of gene expression, researchers have used ß-actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ribosomal RNA (rRNA), or other RNAs as this endogenous control.

> Relative quantitation with data from the ABI PRISM® 7700 Sequence Detection System (using version 1.6 software) can be performed using the standard curve method or the comparative method.

> The availability of distinguishable reporter dyes for the ABI PRISM 7700 Sequence Detection System makes it possible to amplify and detect the target amplicon and the endogenous control amplicon in the same tube (multiplex polymerase chain reaction [PCR]).

Contents This user bulletin describes the following:

- How to use data from amplifications run in separate tubes to illustrate relative quantitation of a target message normalized with an endogenous control. The basic mechanics and mathematics of relative quantitation are presented.
- How the target and endogenous controls can be amplified in the same tube and compared with results of the separate-tube method.

Topic	See page
Relative Quantitation of Gene Expression	1
Standard Curve Method (Separate Tubes)	3
Comparative C _T Method (Separate Tubes)	11
Multiplex PCR (Same Tube)	16
Summary	24
Methods	25
cDNA Synthesis	25
c-myc and GAPDH Amplified in Separate Tubes	27
Limiting Primer Determination	30
c-myc and GAPDH Amplified in the Same Tube	32
Standard Deviation Calculation Using the Standard Curve Method	34
Standard Deviation Calculation Using the Comparative Method	35



Terms Defined The following definitions are assumed in this description of relative quantitation.

Controls/Terms	Definitions		
Standard	A sample of known concentration used to construct a standard curve.		
Reference	A passive or active signal used to normalize experimental results. Endogenous and exogenous controls are examples of active references. Active reference means the signal is generated as the result of PCR amplification. The active reference has its own set of primers and probe.		
	♦ Endogenous control – This is an RNA or DNA that is present in each experimental sample as isolated. By using an endogenous control as an active reference, you can normalize quantitation of a messenger RNA (mRNA) target for differences in the amount of total RNA added to each reaction.		
	♦ Exogenous control – This is a characterized RNA or DNA spiked into each sample at a known concentration. An exogenous active reference is usually an <i>in vitro</i> construct that can be used as an internal positive control (IPC) to distinguish true target negatives from PCR inhibition. An exogenous reference can also be used to normalize for differences in efficiency of sample extraction or complementary DNA (cDNA) synthesis by reverse transcriptase.		
	Whether or not an active reference is used, it is important to use a passive reference containing the dye ROX in order to normalize for non-PCR-related fluctuations in fluorescence signal.		
Calibrator	A sample used as the basis for comparative results.		

Standard Curve Method (Separate Tubes)

Absolute Standard It is possible to use the ABI PRISM 7700 Sequence Detector data to obtain absolute Curve quantitation, but it requires that the absolute quantities of the standard be known by some independent means. Plasmid DNA or in vitro transcribed RNA are commonly used to prepare absolute standards. Concentration is measured by A₂₆₀ and converted to the number of copies using the molecular weight of the DNA or RNA.

> The following critical points must be considered for the proper use of absolute standard curves:

- It is important that the DNA or RNA be a single, pure species. For example, plasmid DNA prepared from E. coli often is contaminated with RNA, which increases the A₂₆₀ measurement and inflates the copy number determined for the plasmid.
- Accurate pipetting is required because the standards must be diluted over several orders of magnitude. Plasmid DNA or in vitro transcribed RNA must be concentrated in order to measure an accurate A_{260} value. This concentrated DNA or RNA must then be diluted 10^6-10^{12} -fold to be at a concentration similar to the target in biological samples.
- The stability of the diluted standards must be considered, especially for RNA. Divide diluted standards into small aliquots, store at -80°C, and thaw only once before use. An example of the effort required to generate trustworthy standards is provided by Collins et al. (Anal. Biochem. 226:120-129, 1995), who report on the steps they used in developing an absolute RNA standard for viral quantitation.
- It is generally not possible to use DNA as a standard for absolute quantitation of RNA because there is no control for the efficiency of the reverse transcription step.

Relative Standard Curve

It is easy to prepare standard curves for relative quantitation because quantity is expressed relative to some basis sample, such as the calibrator. For all experimental samples, target quantity is determined from the standard curve and divided by the target quantity of the calibrator. Thus, the calibrator becomes the 1× sample, and all other quantities are expressed as an *n*-fold difference relative to the calibrator. As an example, in a study of drug effects on expression, the untreated control would be an appropriate calibrator.

Because the sample quantity is divided by the calibrator quantity, the unit from the standard curve drops out. Thus, all that is required of the standards is that their relative dilutions be known. For relative quantitation, this means any stock RNA or DNA containing the appropriate target can be used to prepare standards.

The following critical points must be considered for the proper use of relative standard curves:

- It is important that stock RNA or DNA be accurately diluted, but the units used to express this dilution are irrelevant. If two-fold dilutions of a total RNA preparation from a control cell line are used to construct a standard curve, the units could be the dilution values 1, 0.5, 0.25, 0.125, and so on. By using the same stock RNA or DNA to prepare standard curves for multiple plates, the relative quantities determined can be compared across the plates.
- It is possible to use a DNA standard curve for relative quantitation of RNA. Doing this requires the assumption that the reverse transcription efficiency of the target

is the same in all samples, but the exact value of this efficiency need not be known.

For quantitation normalized to an endogenous control, standard curves are prepared for both the target and the endogenous reference. For each experimental sample, the amount of target and endogenous reference is determined from the appropriate standard curve. Then, the target amount is divided by the endogenous reference amount to obtain a normalized target value.

Again, one of the experimental samples is the calibrator, or 1x sample. Each of the normalized target values is divided by the calibrator normalized target value to generate the relative expression levels.

Curve Example

Relative Standard To illustrate the use of standard curves for relative quantitation, the following example is used: the target is human c-myc mRNA and the endogenous control is human GAPDH mRNA. See the "Methods" section on page 25 for details. Specific instructions for using the standard curve method are in "Constructing a Relative Standard Curve" on page 7.

Plate Setup

Figure 1 shows the plate setup for the relative quantitation of the c-myc mRNA where the target and endogenous reference are amplified in separate tubes. Rows A-D contain c-myc-specific primers and a FAM-labeled c-myc probe. Figure 2 on page 5 shows the plate setup for GAPDH mRNA. Rows E-H contain GAPDH-specific primers and a JOE-labeled probe (TagMan[®] GAPDH Control Reagents, P/N 402869).

Dilutions of a cDNA sample prepared from Raji total RNA are used to construct standard curves for the c-myc and the GAPDH amplifications. The unknown samples are cDNA prepared from total RNA isolated from human brain, kidney, liver, and lung.




Figure 1. Plate setup for relative quantitation of the c-myc mRNA on FAM layer




Figure 2. Plate setup for GAPDH mRNA

Setting Thresholds

After performing the PCR, choose separate thresholds on the FAM and JOE layers (Figures 3 and 4 on page 6) by performing the following steps.

Step	Action
1	Select Analyze from the Analysis menu.
2	Examine the semi-log view of the amplification plots.
3	Adjust the default baseline setting to accommodate the earliest amplification plot.
4	Select a threshold above the noise close to the baseline but still in the linear region of the semi-log plot. Click and drag the threshold line to set the threshold.




Figure 3. Set the threshold on the FAM layer by examining the semi-log view of the amplification plot. Note that the baseline setting has been adjusted to stop at cycle 22.




Figure 4. Set the threshold on the JOE layer by examining the semi-log view of the amplification plot. Note that the baseline setting has been adjusted to stop at cycle 16.

Constructing a Relative Standard Curve

The ABI Prism 7700 Sequence Detection System (version 1.6 software) is not designed to construct two standard curves on the same plate. To analyze this experiment, Results are exported to an Excel spreadsheet by choosing the Export option in the File menu. The exported file contains columns with the sample well number, sample description, standard deviation of the baseline, $\Delta R_{n,}$ and C_{T} . The FAM information is reported first with the JOE information in the rows under the FAM data. The important parameter for quantitation is the C_{T} .

Set up three columns as shown below listing the input amount for the standard curve samples, the log of this input amount, and the C_T value.

Perform the following steps in Excel to construct a standard curve from your data.

Step	Action					
1	Select the log input and CT data as shown below.					
	G	Н		J	1	
	Sample	ng	log ng	Ct	-	
	NTC		,.,	36.61		
	NTC			35.89		
	NTC			40.00		
	Raji-1	1	0	25.63		
	Raji-1	1	0	25.56		
	Raji-1	1	0	25.59		
	Raji-0.5	0.5	-0.30103	26.83		
	Raji-0.5	0.5	-0.30103	26.80		
	Raji-0.5	0.5	-0.30103	26.67		
	Raji-0.2	0.2	-0.69897	28.20		
	Raji-0.2	0.2	-0.69897	28.13		
	Raji-0.2	0.2	-0.69897	28.10		
	Raji-0.1	0.1	-1	29.29		
	Raji-0.1	0.1	-1	29.20		
	Raji-0.1	0.1	-1	29.04		
	Raji-0.05	0.05	-1.30103	30.14		
	Raji-0.05	0.05	-1.30103	30.11		
	Raji-0.05	0.05 0.02	-1.30103	30.17 31.35		
	Raji-0.02	0.02	-1.69897 -1.69897		+	
	Raji-0.02 Raji-0.02	0.02	-1.69897	31.34 31.63		
	Raji-0.02	0.02	-1.09097	32.55		
	Raji-0.01	0.01	-2	32.33		
	Raji-0.01	0.01	-2	32.37		
	Kaji G.Si	0.01		02.01	•	
2	Llaina tha Eva	al Chart Wiz	and draw an V	/ (acattar) nl	at an the work shoot with the	
					ot on the work sheet with the	
	log input amount as the X values and C _T as the Y values.					
	Note The p	olotted graph	shows the dat	a points in a	graphical view.	
3	Click one of the data points that appears in graphical view to select it.					
4	Open the Insert menu and select Trendline to plot a line through the data point.					
5	Go to the Type page and select Linear regression.					
6	Go to the Options page and select the boxes for Display Equation on Chart and Display R-squared Value on Chart.					
7	Compare your	chart to Fig	ure 5 on page 8	3.		




Figure 5. The standard curve for the amplification of the c-myc target detected using a FAM-labeled probe.

Calculating the Input Amount

Perform the following steps to calculate the input amount for unknown samples.

Step	Action				
1	For the line shown in Figure 5, calculate the log input amount by entering the following formula in one cell of the work sheet:				
	= ([cell containing C _T value] -b)/m				
	b = y-intercept of standard curve line				
	m = slope of standard curve line				
	Note In Figure 5, $b = 25.712$ and $m = -3.385$ for the equation $y = mx + b$.				
2	Calculate the input amount by entering the following formula in an adjacent cell:				
	= 10^ [cell containing log input amount]				
	Note The units of the calculated amount are the same as the units used to construct the standard curve, which are nanograms of Total Raji RNA. If it is calculated that an unknown has 0.23 ng of Total Raji RNA, then the sample contains the same amount of c-myc mRNA found in 0.23 ng of the Raji Control RNA.				
3	Repeat the steps to construct a standard curve for the endogenous reference using the C_T values determined with the JOE-labeled GAPDH probe. Refer to Table 1 on page 10.				
4	Because c-myc and GAPDH are amplified in separate tubes, average the c-myc and GAPDH values separately.				
5	Divide the amount of c-myc by the amount of GAPDH to determine the normalized amount of c-myc (c-myc $_{\rm N}$).				

Comparing Samples with a Calibrator

The normalized amount of target (c-myc $_{\rm N}$) is a unitless number that can be used to compare the relative amount of target in different samples. One way to make this comparison is to designate one of the samples as a calibrator. In Table 1 on page 10, brain is designated as the calibrator; brain is arbitrarily chosen because it has the lowest expression level of the target.

Relative Standard Curve Results

Each c-myc_N value in Table 1 is divided by the brain c-myc_N value to give the values in the final column. These results indicate the kidney sample contains $5.5\times$ as much c-myc mRNA as the brain sample, liver $34.2\times$ as much, and lung $15.7\times$ as much.

Perform the following steps to determine relative values.

Step	Action
1	Average the c-myc and GAPDH values from Table 1.
2	Divide the c-myc average by the GAPDH average.
3	Designate the calibrator.
4	Divide the averaged sample value by the averaged calibrator value.

Table 1. Amounts of c-myc and GAPDH in Human Brain, Kidney, Liver, and Lung

Tissue	c-myc ng Total Raji RNA	GAPDH ng Total Raji RNA	c-myc _N Norm. to GAPDH ^a	c-myc _N Rel. to Brain ^b
Brain	0.033	0.51	Norm: to dar bit	Tici. to Brain
Diani	0.043	0.56		
	0.036	0.59		
	0.043	0.53		
	0.039	0.51		
	0.040	0.52		
Average	0.039±0.004	0.54±0.034	0.07±0.008	1.0±0.12
Kidney	0.40	0.96	0.07 ±0.000	1.020.12
	0.41	1.06		
	0.41	1.05		
	0.39	1.07		
	0.42	1.06		
	0.43	0.96		
Average	0.41±0.016	1.02±0.052	0.40±0.025	5.5±0.35
Liver	0.67	0.29		
	0.66	0.28		
	0.70	0.28		
	0.76	0.29		
	0.70	0.26		
	0.68	0.27		
Average	0.70±0.036	0.28±0.013	2.49±0.173	34.2±2.37
Lung	0.97	0.82		
	0.92	0.88		
	0.86	0.78		
	0.89	0.77		
	0.94	0.79		
	0.97	0.80		
Average	0.93±0.044	0.81±0.041	1.15±0.079	15.7±1.09

a. The c-myc $_{\rm N}$ value is determined by dividing the average c-myc value by the average GAPDH value. The standard deviation of the quotient is calculated from the standard deviations of the c-myc and GAPDH values. See "Standard Deviation Calculation Using the Standard Curve Method" on page 34.

b. The calculation of c-myc $_N$ relative to brain involves division by the calibrator value. This is division by an arbitrary constant, so the cv of this result is the same as the cv for c-myc $_N$.

Comparative C_T Method (Separate Tubes)

Curve Method

Similar to Standard The comparative C_T method is similar to the standard curve method, except it uses arithmetic formulas to achieve the same result for relative quantitation.

> It is possible to eliminate the use of standard curves for relative quantitation as long as a validation experiment is performed. See "Validation Experiment" on page 14.

Arithmetic Formulas

The amount of target, normalized to an endogenous reference and relative to a calibrator, is given by:

Derivation of the Formula

The equation that describes the exponential amplification of PCR is:

$$X_n = X_o \times (1 + E_X)^n$$

where:

X _n	=	number of target molecules at cycle n	
X _o	=	initial number of target molecules	
E _X	=	efficiency of target amplification	
n	=	number of cycles	

The threshold cycle (C_T) indicates the fractional cycle number at which the amount of amplified target reaches a fixed threshold. Thus,

$$X_{T} = X_{o} \times (1 + E_{X})^{C_{T,X}} = K_{X}$$

where:

X _T	=	threshold number of target molecules
$C_{T,X}$	=	threshold cycle for target amplification
K _X	=	constant

A similar equation for the endogenous reference reaction is:

$$R_{T} = R_{o} \times (1 + E_{R})^{C_{T,R}} = K_{R}$$

where:

R _T	=	threshold number of reference molecules
R _o	=	initial number of reference molecules
E _R	=	efficiency of reference amplification
C _{T, R}	=	threshold cycle for reference amplification
K _R	=	constant

Dividing X_T by R_T gives the following expression:

$$\frac{X_{T}}{R_{T}} = \frac{X_{o} \times (1 + E_{X})^{C_{T,X}}}{R_{o} \times (1 + E_{R})^{C_{T,R}}} = \frac{K_{X}}{K_{R}} = K$$

The exact values of X_T and R_T depend on a number of factors, including:

- ♦ Reporter dye used in the probe
- ♦ Sequence context effects on the fluorescence properties of the probe
- ♦ Efficiency of probe cleavage
- Purity of the probe
- ♦ Setting of the fluorescence threshold.

Therefore, the constant K does not have to be equal to one.

Assuming efficiencies of the target and the reference are the same:

$$E_X = E_R = E$$
,

$$\frac{X_o}{R_o} \times (1 + E)^{C_{T,X} - C_{T,R}} = K$$

or

$$X_{N} \times (1 + E)^{\Delta C_{T}} = K$$

where:

X _N	=	X_0/R_0 , the normalized amount of target	
ΔC_{T}	=	$C_{T,X}$ - $C_{T,R}$, the difference in threshold cycles for target and reference	

Rearranging gives the following expression:

$$X_{N} = K \times (1 + E)^{-\Delta C_{T}}$$

The final step is to divide the X_N for any sample q by the X_N for the calibrator (cb):

$$\frac{X_{N, q}}{X_{N, cb}} = \frac{K \times (1 + E)^{-\Delta C_{T, q}}}{K \times (1 + E)^{-\Delta C_{T, cb}}} = (1 + E)^{-\Delta \Delta C_{T}}$$

where:

$$\Delta \Delta C_{\mathsf{T}} = \Delta C_{\mathsf{T},\mathsf{q}} - \Delta C_{\mathsf{T},\mathsf{cb}}$$

For amplicons designed and optimized according to Applied Biosystems guidelines (amplicon size < 150 bp), the efficiency is close to one. Therefore, the amount of target, normalized to an endogenous reference and relative to a calibrator, is given by:

Target and Reference

Relative Efficiency of For the $\Delta\Delta C_T$ calculation to be valid, the efficiency of the target amplification and the efficiency of the reference amplification must be approximately equal. A sensitive method for assessing if two amplicons have the same efficiency is to look at how ΔC_T varies with template dilution. The standard curves for c-myc and GAPDH used in the previous section provide the necessary data. Table 2 shows the average C_T value for c-myc and GAPDH at different input amounts.

Table 2. Average C_T Value for c-myc and GAPDH at Different Input Amounts

Input Amount ng Total RNA	c-myc Average C _T	GAPDH Average C _T	ΔC _T c-myc – GAPDH
1.0	25.59±0.04	22.64±0.03	2.95±0.05
0.5	26.77±0.09	23.73±0.05	3.04±0.10
0.2	28.14±0.05	25.12±0.10	3.02±0.11
0.1	29.18±0.13	26.16±0.02	3.01±0.13
0.05	30.14±0.03	27.17±0.06	2.97±0.07
0.02	31.44±0.16	28.62±0.10	2.82±0.19
0.01	32.42±0.12	29.45±0.08	2.97±0.14

Figure 6 on page 14 shows a plot of log input amount versus ΔC_T . If the efficiencies of the two amplicons are approximately equal, the plot of log input amount versus ΔC_T has a slope of approximately zero.

Validation Experiment

Before using the $\Delta\Delta C_T$ method for quantitation, perform a validation experiment like that in Figure 6 to demonstrate that efficiencies of target and reference are approximately equal. The absolute value of the slope of log input amount vs. ΔC_T should be < 0.1. The slope in Figure 6 is 0.0492, which passes this test. Once this is proven, you can use the $\Delta\Delta C_T$ calculation for the relative quantitation of target without running standard curves on the same plate.

If the efficiencies of the two systems are not equal, perform quantitation using the standard curve method. Alternatively, new primers can be designed and synthesized for the less efficient system to try to boost efficiency.




Figure 6. Plot of log input amount versus ΔC_T

 $Comparative \ C_T \ \ \text{The C_T data used to determine the amounts of c-myc and $GAPDH$ mRNA shown in c-myc and c-my$ **Results** Table 1 on page 10 are used to illustrate the $\Delta\Delta C_T$ calculation. Table 3 shows the average C_T results for the human brain, kidney, liver, and lung samples and how these C_{TS} are manipulated to determine ΔC_{T} , $\Delta \Delta C_{T}$, and the relative amount of c-myc mRNA. The results are comparable to the relative c-myc levels determined using the standard curve method.

Table 3. Relative Quantitation Using the Comparative C_T Method

Tissue	c-myc Average C _T	GAPDH Average C _T	ΔC _T c-myc–GAPDH ^e	ΔΔC _T ΔC _T –ΔC _{T, Brain} ^b	c-myc _N Rel. to Brain ^c
Brain	30.49±0.15	23.63±0.09	6.86±0.17	0.00±0.17	1.0 (0.9–1.1)
Kidney	27.03±0.06	22.66±0.08	4.37±0.10	-2.50±0.10	5.6 (5.3–6.0)
Liver	26.25±0.07	24.60±0.07	1.65±0.10	-5.21±0.10	37.0 (34.5–39.7)
Lung	25.83±0.07	23.01±0.07	2.81±0.10	-4.05±0.10	16.5 (15.4–17.7)

a. The ΔC_T value is determined by subtracting the average GAPDH C_T value from the average c-myc C_T value. The standard deviation of the difference is calculated from the standard deviations of the c-myc and GAPDH values. See "Standard Deviation Calculation Using the Comparative Method" on page 35.

b. The calculation of $\Delta\Delta C_T$ involves subtraction by the ΔC_T calibrator value. This is subtraction of an arbitrary constant, so the standard deviation of $\Delta\Delta C_T$ is the same as the standard deviation of the ΔC_T value.

c. The range given for c-myc $_N$ relative to brain is determined by evaluating the expression: $2^{-\Delta \Delta C_T}$ with $\Delta\Delta C_T$ + s and $\Delta\Delta C_T$ - s, where s = the standard deviation of the $\Delta\Delta C_T$ value.

Multiplex PCR (Same Tube)

Multiplex PCR is the use of more than one primer pair in the same tube. You can use this method in relative quantitation where one primer pair amplifies the target and another primer pair amplifies the endogenous reference in the same tube. You can perform a multiplex reaction for both the standard curve method and the comparative method.

Dyes Available for TaqMan Probes

The availability of multiple reporter dyes for TagMan® probes makes it possible to detect amplification of more than one target in the same tube. The reporter dyes currently recommended for probes are 6-FAM, TET, and JOE. These dves are distinguishable from one another because they have different emission wavelength maxima:

- 6-FAM, $\lambda_{max} = 518 \text{ nm}$
- TET, $\lambda_{max} = 538 \text{ nm}$
- JOE, $\lambda_{max} = 554 \text{ nm}$

Multicomponenting

The ABI PRISM 7700 Sequence Detection System software uses a process called multicomponenting to distinguish reporter dyes, the quencher dye TAMRA ($\lambda_{max} = 582$ nm), and the passive reference dye ROX (λ_{max} = 610 nm). Multicomponenting is a mathematical algorithm that uses pure dye reference spectra to calculate the contribution of each dye to a complex experimental spectrum.

Quantitation

Accurate Because of experimental variation in measuring both the reference spectra and the sample spectra, multicomponenting introduces some error into the determination of each dye's contribution. The degree of error depends on how well the various dyes are spectrally resolved. The greater the spectral overlap between two dyes, the greater the error. Thus, for the most accurate quantitation using two probes in one tube, use the reporter dyes that have the largest difference in emission maximum: 6-FAM and JOE.

> The TagMan GAPDH Control Reagents (P/N 402869) provide a JOE-labeled probe for human GAPDH mRNA. Therefore, when using GAPDH as an endogenous reference, label the probe for the target mRNA with 6-FAM.

Avoiding **Competition** in Reactions

Reactions to amplify two different segments in the same tube share common reagents. If the two segments have different initial copy numbers, it is possible for the more abundant species to use up these common reagents, impairing amplification of the rarer species. For accurate quantitation, it is important that the two reactions do not compete. Competition can be avoided by limiting the concentration of primers used in the amplification reactions.

Limiting Primer Figure 7 shows PCR amplifications with decreasing concentrations of primers. At Concept 120 and 80 nM, the amplification plots are similar, indicating that the reactions are not limited by the amount of primers. The remaining plots show that the more dilute the primers, the lower the plateau fluorescence level at the end of the reaction. This demonstrates that a lower primer concentration limits the reaction, forcing it to plateau at a lower level of product.




Figure 7. PCR amplifications with decreasing primer concentrations

In terms of kinetic analysis, however, all the reactions except 4 nM have the same C_T value. The strategy for performing two independent reactions in the same tube is to adjust the primer concentrations such that accurate C_Ts are obtained, but soon after that, the exhaustion of primers defines the end of the reaction. In this way, amplification of the majority species is stopped before it can limit the common reactants available for amplification of the minority species.

Considering Relative Abundance of the Target and Reference

In applying the limiting primer concept to target and endogenous reference amplification, the relative abundance of the two species must be considered. For quantitation of gene expression, it is possible to use rRNA as an endogenous reference. The concentration of rRNA in total RNA is always greater than the concentration of any target mRNA. Therefore, in multiplex reactions amplifying both target and rRNA, only the concentrations of the rRNA primers need to be limited. For c-myc and GAPDH, it is not known if the abundance of one RNA is always greater than the other in the tissues and cell lines that might be examined. For amplifying c-myc and GAPDH in the same tube, limiting primer concentrations need to be defined for both amplicons.

Defining Limiting Primer Concentrations

Define limiting primer concentrations by running a matrix of forward and reverse primer concentrations. The desired concentrations are those that show a reduction in ΔR_n but little effect on C_T. Figure 8 on page 18 and Figure 9 on page 19 show the results when GAPDH is amplified using all combinations of forward and reverse primers at 80, 40, 30, and 20 nM.




Figure 8. GAPDH amplified using all combinations of forward and reverse primers

The C_T results in Figure 8 show that the C_T value using 30 nM each primer is the same as 80 nM each primer. Figure 9 shows that the ΔR_n at 30 nM each primer is reduced relative to more concentrated primers. Thus, by amplifying GAPDH with 30 nM each primer, accurate C_T s are obtained, but the GAPDH reaction is shut down before it affects amplification of a less abundant species. In order to provide a margin for error, a concentration of 40 nM each GAPDH primer is used in the "Multiplex PCR Example" on page 19.




Figure 9. GAPDH uplifted using all combinations of forward and reverse primers

A similar experiment defines 50 nM each primer as limiting primer conditions for amplification of c-myc. In these primer limitation studies, the buffer and thermal cycling conditions are the same for the two systems run in the same tube. This process is simplified by using a two-step RT-PCR protocol, because the PCR can be optimized separately from the reverse transcriptase reaction. This allows you to use our Assay Design Guidelines for DNA amplification when they become available (currently in progress). These generate primers and probes that work well using a generic set of buffer and thermal cycling conditions.

If limiting primer concentrations cannot be found, quantitation can still be obtained by running the reactions in separate tubes. Alternatively, the primers can be redesigned and retested to find limiting concentrations. The primers generally need to be altered by increasing their length one or two nucleotides in order to increase their T_Ms.

Example

Multiplex PCR The experiment quantitating the target c-myc normalized to the endogenous reference GAPDH is repeated running both amplifications in the same tube. See Figure 1 on page 4 for the setup on the FAM layer and see Figure 10 on page 20 for the setup on the JOE layer. Figure 10 is similar to the setup in Figure 2 on page 5, except GAPDH is being amplified in rows A-D (the same tubes where amplification of c-myc is being performed). This illustrates one advantage of performing target and reference reaction in the same tube—higher throughput.

> Higher throughput is most evident if you are interested in analyzing a single target because the number of sample tubes is reduced by a factor of two. As the number of targets analyzed on the same plate increases, the advantage of same tube over separate tube decreases, because a single set of reference reactions can be used to normalize all of the different target reactions.

	1	2	3	4	5	6	7	8	9	10	11	12
٨	NTC2 A1	NTC2 A2	NTC2 A3	STD2 1000 pg	STD2 1000 pg	STD2 1000 pg	STD2 500 pg	STD2 500 pg	STD2 500 pg	STD2 200 pg	STD2 200 pg	STD2 200 pg
В	STD2 100 pg	STD2 100 pg	STD2 100 pg	STD2 50 pg	STD2 50 pg	STD2 50 pg	STD2 20 pg	STD2 20 pg	STD2 20 pg	STD2 10 pg	STD2 10 pg	STD2 10 pg
С	GAPDH Brain	GAPDH Brain	GAPDH Brain	GAPDH Brain	GAPDH Brain	GAPDH Brain	GAPDH Kidney	GAPDH Kidney	GAPDH Kidney	GAPDH Kidney	GAPDH Kidney	GAPDH Kidney
D	GAPDH Liver	GAPDH Liver	GAPDH Liver	GAPDH Liver	GAPDH Liver	GAPDH Liver	GAPDH Lung	GAPDH Lung	GAPDH Lung	GAPDH Lung	GAPDH Lung	GAPDH Lung
E												
F												
G												
н												


Figure 10. Plate setup for relative quantitation of the c-myc mRNA on JOE layer

Spectral Compensation Feature

When analyzing data that have two reporters in the same tube, use the special software feature called Spectral Compensation. This is an enhancement of the multicomponenting algorithm because it provides improved well-to-well spectral resolution for multi-reporter applications. However, it can also be a liability because it increases noise of the fluorescence measurements.

With multiple reporter dyes in the same tube, Spectral Compensation should be turned on because accurate separation of dye signals is more important than increased precision. When one reporter dye is used in a tube, Spectral Compensation should be left off in order to benefit from the improved precision.

Perform the following steps to access Spectral Compensation.



Data Handling

After the analysis is performed, setting the baselines and thresholds, exporting the data to Excel, and drawing standard curves in Excel are exactly the same as in the separate tube example. For both the standard curve and $\Delta\Delta C_T$ method, the only difference between same-tube and separate-tube analysis is how replicates are averaged.

Multiplex PCR Results (Standard Curve Method)

Table 4 on page 22 shows the results of the same-tube experiment using the standard curve method. Both the c-myc and GAPDH amounts are determined from a single tube where the amount of sample added must be the same for the two determinations. In another tube, the amount of sample added can be different because of pipetting errors. Therefore, for data obtained in the same tube, it makes sense to divide the target amount by the reference amount for that tube before averaging data from replicate samples. This is illustrated in Table 4 where c-myc $_{\rm N}$ is determined separately for each well and these values are averaged for the six replicates.

Table 4. Relative Quantitation Using Multiplex Reactions (Same Tube) with the Standard Curve Method

Tissue	c-myc ng Total Raji RNA	GAPDH ng Total Raji RNA	c-myc _N Norm. to GAPDH	c-myc _N Rel. to Brain
Brain	0.031	0.618	0.05	
	0.038	0.532	0.07	
	0.032	0.521	0.06	
	0.038	0.550	0.07	
	0.032	0.577	0.06	
	0.037	0.532	0.07	
Average			0.06±0.008	1.0±0.14
Kidney	0.365	0.049	0.35	
	0.338	1.035	0.33	
	0.423	1.042	0.41	
	0.334	1.086	0.31	
	0.334	1.021	0.33	
	0.372	1.139	0.33	
Average			0.34±0.035	5.4±0.55
Liver	0.477	0.255	1.87	
	0.471	0.228	2.06	
	0.535	0.258	2.07	
	0.589	0.241	2.44	
	0.539	0.264	2.04	
	0.465	0.227	2.05	
Average			2.09±0.186	33.3±2.97
Lung	0.853	0.085	0.97	
	0.900	0.084	0.88	
	0.956	0.082	1.00	
	0.900	0.093	0.87	
	0.996	0.112	0.87	
	0.859	0.090	0.84	
Average			0.90±0.062	14.4±0.99

$Multiplex\ PCR\ Results\ (Comparative\ C_T\ Method)$

Table 5 on page 23 shows the $\Delta\Delta C_T$ calculations for the same-tube experiment. Because c-myc and GAPDH data are being obtained from the same tube, calculations are carried out individually for each well before averaging.

Table 5. Relative Quantitation Using Multiplex Reactions (Same Tube) with the Comparative ($\Delta\Delta C_T$) Method

Tissue	c-myc C _T	GAPDH C _T	ΔC _T c-myc - GAPDH	$\begin{array}{c} \Delta\Delta C_T \\ \Delta C_T \text{ - Avg. } \Delta C_T, \\ \text{Brain} \end{array}$	c-myc _N Rel. to Brain
 Brain	32.38	25.07	7.31		
	32.08	25.29	6.79		
	32.35	25.32	7.03		
	32.08	25.24	6.84		
	32.34	25.17	7.17		
	32.13	25.29	6.84		
Average			6.93±0.16	0.00±0.16	1.0 (09–1.1)
Kidney	28.73	24.30	4.43		
	28.84	24.32	4.52		
	28.51	24.31	4.20		
	28.86	24.25	4.61		
	28.86	24.34	4.52		
	28.70	24.18	4.52		
Average			4.47±0.14	-2.47±0.14	5.5 (5.0–6.1)
Liver	28.33	26.36	1.97		
	28.35	26.52	1.83		
	28.16	26.34	1.82		
	28.02	26.44	1.58		
	28.15	26.31	1.84		
	28.37	26.53	1.84		
Average			1.81±0.13	-5.12±0.13	34.8 (31.9–38.0)
Lung	27.47	24.55	2.92		
	27.39	24.33	3.06		
	27.30	24.43	2.87		
	27.39	24.32	3.07		
	27.24	24.18	3.06		
	27.46	24.34	3.12		
Average			3.02±0.10	-3.92±0.10	15.1 (14.1–16.2)

Summary

Figure 11 shows a comparison of the four different methods used to determine the relative quantity of c-myc mRNA. Whether the analysis is done in one or two tubes or with the standard curve or comparative C_T methods, there are no significant differences in the results.

Comparison of Different Methods for Relative Quantitation

Figure 11. Comparison of four methods for relative quantitation

Kidney

Brain

Determining Which Method to Use

The decision of which protocol to use for relative quantitation does not depend on which method gives the best results. All methods can give equivalent results.

Running the target and endogenous control amplifications in separate tubes and using the standard curve method of analysis requires the least amount of optimization and validation.

Liver

To use the comparative C_T method, a validation experiment must be run to show that the efficiencies of the target and endogenous control amplifications are approximately equal. The advantage of using the comparative C_T method is that the need for a standard curve is eliminated. This increases throughput because wells no longer need to be used for the standard curve samples. It also eliminates the adverse effect of any dilution errors made in creating the standard curve samples.

To amplify the target and endogenous control in the same tube, limiting primer concentrations must be identified and shown not to affect C_T values. By running the two reactions in the same tube, throughput is increased and the effects of pipetting errors are reduced. A drawback of using the multiplex PCR is that it does introduce some errors into the final results due to multicomponenting.

Lung

Methods

Introduction This section contains the detailed protocols used to generate the data reported in this User Bulletin.

cDNA Synthesis

Sources Human brain, kidney, liver, and lung total RNA are from Clontech, which provides total RNA as an ethanol precipitate. Raji total RNA at 50 ng/ μ L is from the TaqMan[®] GAPDH Control Reagents Kit (P/N 402869).

> The reagents (other than H₂O) for preparing the following Master Mixes are from the TagMan® Reverse Transcription Reagents Kit (P/N N808-0234).

Preparation

Master Mix For each Master Mix, make enough reagent for six samples. This includes one extra reaction volume to accommodate reagent losses during pipetting.

+RT Master Mix

Components	Volume (<i>µ</i> L)	Concentration in Final Reaction
DEPC H ₂ O	111	
10× TaqMan [®] RT buffer	60	1×
25 mM MgCl ₂	132	5.5 mM
deoxyNTPs mixture (2.5 mM each dNTP)	120	500 μ M each dNTP
50 μ M Random Hexamers	30	$2.5~\mu\mathrm{M}$
RNase Inhibitor (20 U/µL)	12	0.4 U/μL
MultiScribe™ Reverse Transcriptase (50 U/μL)	15	1.25 U/ <i>μ</i> L

-RT Master Mix

Components	Volume (μL)	Concentration in Final Reaction
DEPC H ₂ O	126	
10× TaqMan RT buffer	60	1×
25 mM MgCl ₂	132	5.5 mM
deoxyNTPs mixture (2.5 mM each dNTP)	120	500 μ M each dNTP
50 μ M Random Hexamers	30	$2.5~\mu M$
RNase Inhibitor (20 U/µL)	12	0.4 U/μL

Tissue RNA page 25.

Preparation of Perform the following steps for each tissue RNA listed in the Master Mix tables on

Step	Action
1	Vigorously vortex the RNA suspension.
2	Transfer 40 μ L to a microcentrifuge tube and centrifuge for 10 minutes at 14,000 rpm.
3	Discard the supernatant of each sample and allow the RNA pellet to air dry.
4	Dissolve each RNA sample in 200 μ L of DEPC H ₂ O (Ambion) and keep on ice.

Procedure for cDNA Perform the following steps for cDNA synthesis. Samples prepared using this Synthesis procedure are stable at 4°C for at least one month.

Step	Action						
1	For each total RNA sample (human brain, kidney, liver, lung, and Raji), transfer 20 μ L (1 μ g) to each of two MicroAmp [®] tubes (10 tubes total).						
2	Add 80 μ L of +RT Master Mix to five tubes.						
3	Add 80 μ L of -RT Master Mix to five tubes.						
	Note The -RT control reactions are important for assessing how much contaminating genomic DNA is present in each total RNA sample.						
4	Incubate the reactions in the GeneAmp® PCR System 9600 at:						
	♦ 25°C, 10 minutes						
	♦ 48°C, 30 minutes						
	♦ 95°C, 5 minutes						
5	Add 2 μ L of 0.5 M EDTA to each reaction. Store the cDNA samples at 4°C for one month.						

Note The designated concentration of each sample is 10 ng cDNA/ μ L, which means 1 μ L of sample contains the cDNA obtained from 10 ng total RNA.

c-myc and GAPDH Amplified in Separate Tubes

Sources The primers (P/N 450005, 450004, or 450021) and TaqMan[®] probe (P/N 450003, 450024, or 450025) used to amplify and detect c-myc are from the Custom Oligonucleotide Synthesis Service of Applied Biosystems. The sequences are given below.

> c-myc Forward Primer TCAAGAGGTGCCACGTCTCC c-myc Reverse Primer **TCTTGGCAGCAGGATAGTCCTT**

c-myc Probe FAM-CAGCACAACTACGCAGCGCCTCC-TAMRA

The primers and probe used to amplify and detect GAPDH are from the TagMan GAPDH Control Reagents Kit (P/N 402869). The sequences are given below.

GAPDH Forward Primer GAAGGTGAAGGTCGGAGTC **GAPDH Reverse Primer** GAAGATGGTGATGGGATTTC

JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA GAPDH Probe

Except for primers, probes, H₂O, and gelatin, the reagents for preparing the following Master Mixes are from the TagMan® PCR Core Reagent Kit (P/N N808-0228).

Master Mix For each Master Mix, make enough reagent for 60 samples. This includes 12 extra Preparation reaction volumes to accommodate reagent losses during pipetting.

c-myc Master Mix

Components	Volume (<i>µ</i> L)	Concentration in Final Reaction
H ₂ O	1658.5	
10x TaqMan buffer A	300	1×
25 mM MgCl ₂	660	5.5 mM
2% gelatin (Sigma G1393)	75	0.05%
10 mM dATP	60	200 μ M
10 mM dCTP	60	$200~\mu{ m M}$
10 mM dGTP	60	$200~\mu{ m M}$
20 mM dUTP	60	400 μ M
168 μM c-myc Probe	1.8	100 nM
252 μ M c-myc Forward Primer	2.4	200 nM
257 μ M c-myc Reverse Primer	2.3	200 nM
AmpErase [®] UNG	30	0.01 U/ <i>μ</i> L
AmpliTaq Gold [™]	30	0.05 U/μL

GAPDH Master Mix

Components	Volume (μL)	Concentration in Final Reaction
H ₂ O	1385	
10× TaqMan buffer A	300	1×
25 mM MgCl ₂	660	5.5 mM
2% gelatin	75	0.05%
10 mM dATP	60	$200~\mu M$
10 mM dCTP	60	$200~\mu M$
10 mM dGTP	60	$200~\mu M$
20 mM dUTP	60	$400~\mu \mathrm{M}$
5 μ M GAPDH Probe	60	100 nM
10 μ M GAPDH Forward Primer	60	200 nM
10 μM GAPDH Reverse Primer	60	200 nM
AmpErase UNG	30	0.01 U/µL
AmpliTaq Gold	30	0.05 U/μL

Procedure Follow this procedure to amplify the target and reference in separate tubes.

Step	Action									
1					der to constructing/mL of yeast					
	2 μL	10	ng/μL	Raji cDNA	+	18 μL 50 ng/μL	yeast RNA	⇒	1	ng/μL
	10 μL	1	ng/μL	Raji cDNA	+	10 μL 50 ng/μL	yeast RNA	⇒	0.5	ng/μL
	8 <i>µ</i> L	0.5	ng/μL	Raji cDNA	+	12 μL 50 ng/μL	yeast RNA	⇒	0.2	ng/μL
	10 μL	0.2	ng/μL	Raji cDNA	+	10 μL 50 ng/μL	yeast RNA	⇒	0.1	ng/μL
	10 μL	0.1	ng/μL	Raji cDNA	+	10 μL 50 ng/μL	yeast RNA	⇒	0.05	ng/μL
	8 <i>μ</i> L	0.05	ng/μL	Raji cDNA	+	12 μL 50 ng/μL	yeast RNA	⇒	0.02	ng/μL
	10 μL	0.02	ng/μL	Raji cDNA	+	10 μL 50 ng/μL	yeast RNA	⇒	0.01	ng/μL
2	175 μL c	-myc Ma	aster Mix			amplifying c-m 50 ng/µL yeast RN		⇒ ;	50 <i>μ</i> L to	A1-3
	175 μL c	-myc Ma	aster Mix	+	3.5 μL	1 ng/μL Raji cDNA		⇒ :	50 μL to	A4-6
	175 μL c					0.5 ng/μL Raji cDN			50 μL to	
	175 μL c					0.2 ng/μL Raji cDN		⇒ :	50 μL to	A10-12
	175 μL c			+	3.5 <i>µ</i> L	0.1 ng/μL Raji cDN	Α	⇒ :	50 μL to	B1-3
	175 μL c	-			•	0.05 ng/μL Raji cD			50 μL to	
	175 μL c	-mvc Ma	aster Mix		$3.5 \mu L$	0.02 ng/µL Raji cD	NA	⇒ :	50 μ L to	B7-9
		,		+		<u> </u>				
	175 μL c		aster Mix		3.5 <i>µ</i> L	0.01 ng/μL Raji cD		⇒ ;	50 μL to	B10-12
	325 µL c	-myc Ma	aster Mix	+		0.01 ng/μL Raji cD 10 ng/μL brain cDN	NA		50 μL to 50 μL to	
	<u>'</u>	-myc Ma	aster Mix	+	6.5 <i>µ</i> L	<u> </u>	NA NA	⇒ ;		C1-6
	325 µL c	-myc Ma -myc Ma -myc Ma	aster Mix aster Mix	+ + +	6.5 μL 6.5 μL	10 ng/μL brain cDN	NA NA DNA	⇒ ;	, 50 μL to	C1-6 C7-12

Step	Action	
3	Set up the PCR tray for the reactions amplifying GAPDH.	
	175 μL GAPDH Master Mix + 3.5 μL 50 ng/μL yeast RNA	⇒ 50 μL to E1-3
	175 μL GAPDH Master Mix + 3.5 μL 1 ng/μL Raji cDNA	\Rightarrow 50 μ L to E4-6
	175 μL GAPDH Master Mix + 3.5 μL 0.5 ng/μL Raji cDNA	⇒ 50 μL to E7-9
	175 μL GAPDH Master Mix + 3.5 μL 0.2 ng/μL Raji cDNA	\Rightarrow 50 μ L to E10-12
	175 μL GAPDH Master Mix + 3.5 μL 0.1 ng/μL Raji cDNA	\Rightarrow 50 μ L to F1-3
	175 μL GAPDH Master Mix + 3.5 μL 0.05 ng/μL Raji cDNA	⇒ 50 μL to F4-6
	175 μL GAPDH Master Mix + 3.5 μL 0.02 ng/μL Raji cDNA	⇒ 50 μL to F7-9
	175 μL GAPDH Master Mix + 3.5 μL 0.01 ng/μL Raji cDNA	⇒ 50 µL to F10-12
	325 μL GAPDH Master Mix + 6.5 μL 10 ng/μL brain cDNA	⇒ 50 μL to G1-6
	325 μL GAPDH Master Mix + 6.5 μL 10 ng/μL kidney cDNA	\Rightarrow 50 μ L to G7-12
	325 μL GAPDH Master Mix + 6.5 μL 10 ng/μL liver cDNA	\Rightarrow 50 μ L to H1-6
	325 μL GAPDH Master Mix + 6.5 μL 10 ng/μL lung cDNA	\Rightarrow 50 μ L to H7-12
4	Set up the thermal cycling conditions for the ABI PRISM® 770	00 Sequence Detector:
	♦ 50°C, 2 minutes	
	♦ 95°C, 10 minutes	
	Then set up 40 cycles of the following:	
	♦ 95°C, 15 seconds	
	♦ 60°C, 1 minute	

Limiting Primer Determination

Master Mix For each Master Mix, make enough reagent for 76 samples. This includes 16 extra Preparation reaction volumes to accommodate reagent losses during pipetting.

Master Mix

Components	Volume (µL)	Concentration in Final Reaction
H ₂ O	1271.1	
10× TaqMan buffer A	380	1×
25 mM MgCl ₂	836	5.5 mM
2% gelatin (Sigma G1393)	95	0.05%
10 mM dATP	76	200 μM
10 mM dCTP	76	200 μM
10 mM dGTP	76	200 μM
20 mM dUTP	76	400 μ M
5 μM GAPDH Probe	76	100 nM
AmpErase UNG	38	0.01 U/µL
AmpliTaq Gold	38	0.05 U/µL
10 ng/μL Raji cDNA	1.9	0.25 ng per rxn

Procedure Follow this procedure to limit primers.

Step	Action						
1	Prepare a separate dilution s primers.	series 1	for each of th	e forwa	rd and	reverse GAPDI	1
	32 μL 10 μM Primer	+	368 µL	H ₂ O	⇒	800 nM	
	75 μL 800 nM Primer	+	25 μL	H ₂ O	⇒	600 nM	
	62.5 µL 800 nM Primer	+	37.5 μL	H ₂ O	⇒	500 nM	
	50 μL 800 nM Primer	+	50 μL	H ₂ O	⇒	400 nM	
	37.5 µL 800 nM Primer	+	62.5 μL	H ₂ O	⇒	300 nM	
	25 μL 800 nM Primer	+	75 μL	H ₂ O	\Rightarrow	200 nM	
2	Add to wells in the PCR tray:						
	♦ 5 μL of 800 nM GAPDH	Forwa	ard Primer to	A1-12			
	♦ 5 <i>μ</i> L of 600 nM GAPDH	Forwa	ard Primer to	B1-12			
	♦ 5 μL of 500 nM GAPDH	Forwa	ard Primer to	C1-12			
	♦ 5 <i>μ</i> L of 400 nM GAPDH	Forwa	ard Primer to	D1-12			
	♦ 5 μL of 300 nM GAPDH	Forwa	ard Primer to	E1-12			
	♦ 5 <i>μ</i> L of 200 nM GAPDH	Forwa	ard Primer to	F1–12			

Step	Action			
3	Add to wells in the PCR tray:			
	♦ 5 μL of 800 nM GAPDH Reverse Primer to 1,2A–F			
	♦ 5 μL of 600 nM GAPDH Reverse Primer to 3,4A–F			
	♦ 5 μL of 500 nM GAPDH Reverse Primer to 5,6A–F			
	♦ 5 μL of 400 nM GAPDH Reverse Primer to 7,8A–F			
	♦ 5 μL of 300 nM GAPDH Reverse Primer to 9,10A–F			
	♦ 5 μL of 200 nM GAPDH Reverse Primer to 11,12A–F			
4	Add 40 μ L of Master Mix to each reaction tube.			
5	Set up the thermal cycling conditions for the ABI PRISM 7700 Sequence Detector:			
	♦ 50°C, 2 minutes			
	♦ 95°C, 10 minutes			
	Then set up 40 cycles of the following:			
	♦ 95°C, 15 seconds			
	♦ 60°C, 1 minute			

Note In Figure 8 on page 18 and Figure 9 on page 19, only the 20-, 30-, 40-, and 80-nM results are shown.

c-myc and GAPDH Amplified in the Same Tube

Master Mix For each Master Mix, make enough reagent for 60 samples. This includes 12 extra Preparation reaction volumes to accommodate reagent losses during pipetting.

Master Mix

Components	Volume (µL)	Concentration in Final Reaction
H ₂ O	1549.2	
10× TaqMan buffer A	300	1×
25 mM MgCl ₂	660	5.5 mM
2% gelatin (Sigma G1393)	75	0.05%
10 mM dATP	60	200 μ M
10 mM dCTP	60	200 μ M
10 mM dGTP	60	200 μ M
20 mM dUTP	60	400 μ M
168 μM c-myc Probe	1.8	100 nM
10 μ M c-myc Forward Primer	15	50 nM
10 μ M c-myc Reverse Primer	15	50 nM
5 μM GAPDH Probe	60	100 nM
10 μ M GAPDH Forward Primer	12	40 nM
10 μ M GAPDH Reverse Primer	12	40 nM
AmpErase UNG	30	0.01 U/ <i>μ</i> L
AmpliTaq Gold	30	0.05 U/ <i>μ</i> L

Procedure Follow this procedure to amplify the target and reference in the same tube.

S	tep	Action				
	1	Prepare dilutions of Reexperiment.	aji cDN	NA for th	e standard curves as in	the Separate Tube
	2	Set up the PCR tray:				
		175 µL Master Mix	+	3.5 <i>μ</i> L	50 ng/μL yeast RNA	\Rightarrow 50 μ L to A1-3
		175 μL Master Mix	+	3.5μ L	1 ng/μL Raji cDNA	\Rightarrow 50 μ L to A4-6
		175 μL Master Mix	+	3.5 <i>µ</i> L	0.5 ng/μL Raji cDNA	\Rightarrow 50 μ L to A7-9
		175 μL Master Mix	+	3.5μ L	0.2 ng/μL Raji cDNA	\Rightarrow 50 μ L to A10-12
		175 μL Master Mix	+	3.5μ L	0.1 ng/μL Raji cDNA	\Rightarrow 50 μ L to B1-3
		175 μL Master Mix	+	3.5 <i>µ</i> L	0.05 ng/μL Raji cDNA	⇒ 50 μL to B4-6
		175 μL Master Mix	+	3.5μ L	0.02 ng/μL Raji cDNA	\Rightarrow 50 μ L to B7-9
		175 μL Master Mix	+	3.5μ L	0.01 ng/μL Raji cDNA	\Rightarrow 50 μ L to B10-12
		325 µL Master Mix	+	$6.5~\mu$ L	10 ng/μL brain cDNA	\Rightarrow 50 μ L to C1-6
		325 µL Master Mix	+	$6.5~\mu$ L	10 ng/μL kidney cDNA	\Rightarrow 50 μ L to C7-12
		325 µL Master Mix	+	6.5 <i>μ</i> L	10 ng/μL liver cDNA	\Rightarrow 50 μ L to D1-6
		325 µL Master Mix	+	6.5 <i>μ</i> L	10 ng/μL lung cDNA	\Rightarrow 50 μ L to D7-12
_						

Step	Action			
3	Set up the thermal cycling conditions for the ABI PRISM 7700 Sequence Detector:			
	♦ 50°C, 2 minutes			
	♦ 95°C, 10 minutes			
	Then set up 40 cycles of the following:			
	♦ 95°C, 15 seconds			
	♦ 60°C, 1 minute			

Standard Deviation Calculation Using the Standard Curve Method

Formula The c-myc_N value is determined by dividing the average c-myc value by the average GAPDH value. The standard deviation of the quotient is calculated from the standard deviations of the c-myc and GAPDH values using the following formula:

$$cv = \sqrt{cv_1^2 + cv_2^2}$$

where:

$$cv = \frac{s}{\overline{X}} = \frac{stddev}{meanvalue}$$

As an example, from Table 1 on page 10 (brain sample):

$$cv_1 = \frac{0.004}{0.039}$$

and

$$cv_2 = \frac{0.034}{0.54}$$

$$cv = \sqrt{\left(\frac{0.004}{0.039}\right)^2 + \left(\frac{0.034}{0.54}\right)^2} = 0.12$$

since

$$cv = \frac{s}{\overline{X}}$$

$$s = (cv)(\overline{X})$$

$$s = (0.12)(0.07)$$

$$s = 0.008$$

Standard Deviation Calculation Using the Comparative Method

Formula The ΔC_T value is determined by subtracting the average GAPDH C_T value from the average c-myc C_T value. The standard deviation of the difference is calculated from the standard deviations of the c-myc and GAPDH values using the following formula:

$$s = \sqrt{s_1^2 + s_2^2}$$

where:

s = std dev

As an example, from Table 3 on page 15 (brain sample):

$$s_1 = 0.15$$

and

$$s_2 = 0.09$$

$$s = \sqrt{(0.15)^2 + (0.09)^2} = 0.17$$

© Copyright 2001. Applied Biosystems. All rights reserved. For Research Use Only. Not for use in diagnostic procedures. The PCR process is covered by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche Ltd. ABI and MultiScribe are trademarks of Applera Corporation or its subsidiaries in the U.S. and certain other countries. ABI PRISM and its design, Applied Biosystems and MicroAmp are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and certain other countries.

AmpErase, AmpliTaq, AmpliTaq Gold, GeneAmp, and TaqMan are registered trademarks of Roche Molecular Systems.

P/N 4303859B, Stock No. 777802-002